Alabama Dept. of Public Health reports no measles detected after investigation
The ADPH says that due to the extremely contagious risk of measles in unvaccinated people, they regularly launch investigations on suspected cases to ensure that vulnerable and potentially exposed people are informed and protected.
'This investigation began on Saturday afternoon. I appreciate the quick response of the ADPH on call team to ensure that all the response elements were in place, in order to protect Alabama.' ADPH Chief Medical Officer, Dr. Karen Landers said. 'While ADPH has determined that this is not a case of measles, I urge all Alabamians to be vigilant in ensuring that eligible persons are up to date on the MMR vaccine. The MMR vaccine is safe and effective. High rates of MMR vaccine in our state will protect our children, our families, and our citizens from this severe and deadly disease.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Parents urged to get kids vaccinated after Liverpool death
Parents in Wiltshire are being urged to ensure their children's vaccinations are up to date after a child in Liverpool died from measles. Measles is highly contagious and the effects can be fatal, medics warn. Measles, Mumps, and Rubella vaccinations are offered to children in two stages. The first dose, MMR1, is typically given around 12 months of age, while the second dose, MMR2, is usually administered around three years of age. Both doses are necessary for optimal protection against these three viral diseases. The World Health Organisation says at least 95 per cent of children in a community should be vaccinated to ensure herd immunity because measles is so contagious. In Wiltshire, vaccination rates are well above the South West and UK averages, but still dip below the 95 per cent target for the MMR2 jab. In the year 2023-24, 96.3 per cent of children in the county had received their MMR1 jab by the age of five, while 92 per cent had received the MMR2 vaccination. In Wiltshire, vaccination rates climbed to an all-time high in 2020-21 and 2021-22 before declining slightly. MMR 1 vaccination rates increased marginally between 2022-23 and 2023-24 but MMR 2 vaccination rates declined slightly. In the South West, there were 112 laboratory confirmed measles cases in 2024, with 40 of those cases being reported in children aged five and under. In 2025 so far, there have been 58 laboratory confirmed measles cases, with children under five accounting for 29 cases. Fewer than 10 cases were reported in Wiltshire, so the county does not feature individually in health statistics. The UK Health Security Agency is responsible for monitoring the disease, promoting vaccination, and responding to outbreaks. In a statement, the UKHSA South West said: 'Measles is highly contagious and can cause serious complications. 'It is preventable with the MMR vaccine, so parents should make sure their children are up to date and catch up on any missed doses.' Symptoms to look out for include cold-like symptoms, followed by a rash a few days later. Some people may also get small spots in their mouth. This progresses with a distinctive rash that starts on the face or behind the ears and then spreads to the rest of the body. Measles can leave people seriously ill and even be fatal. While the incident in Liverpool is only the second reported death of a child from measles in the past five years, health authorities are concerned about the UK's low vaccination rate. In Liverpool, only 73 per cent of children aged five have received the necessary two shots, while in parts of London – where over 1,300 cases of measles were reported last year – vaccine uptake is below 65 per cent.
Business Wire
2 days ago
- Business Wire
Acadia Healthcare Announces Date for Second Quarter 2025 Earnings Release
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2025 results on Tuesday, August 5, 2025, after the close of the market. Acadia will conduct a conference call with institutional investors and analysts at 9:00 a.m. ET on Wednesday, August 6, 2025. A live broadcast of the conference call will be available at in the 'Investors' section of the website. The webcast of the conference call will be available for 30 days. About Acadia Healthcare Acadia is a leading provider of behavioral healthcare services across the United States. As of March 31, 2025, Acadia operated a network of 270 behavioral healthcare facilities with approximately 12,000 beds in 39 states and Puerto Rico. With approximately 25,500 employees serving more than 82,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Business Wire
3 days ago
- Business Wire
CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced the release of a proposed draft Local Coverage Determination (LCD) related to molecular testing for solid organ allograft rejection. There is no change in current coverage and the draft LCD is open for comment through August 31, 2025. The draft policy would continue to provide coverage for surveillance testing for kidney, heart, and lung transplant patients without a tie to protocol biopsy, underscoring the value of this important non-invasive molecular testing for solid organ transplant patients. In addition, the draft policy introduces a bundled payment concept for surveillance testing. The Company is reviewing the draft coverage and payment policy and anticipates providing additional information during its upcoming earnings call on August 6, 2025. 'We believe publication of this draft policy solidifies coverage for surveillance testing and supports our longstanding position that our tests improve health outcomes for transplant patients,' said John W. Hanna, President and CEO of CareDx. 'We do not expect changes in the use of our testing in response to this draft LCD and remain deeply committed to patient care and providing access to our testing. We look forward to providing feedback on the draft LCD through the public comment process.' The proposed LCD is available at: About CareDx – The Transplant Company™ CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: Forward Looking Statement This press release includes forward-looking statements, including statements regarding the potential benefits and results that may be achieved with AlloSure ®, AlloMap ® and HeartCare ®, the use of our tests, and reimbursement coverage. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx's control, that could cause the actual results to differ materially from those projected, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx's filings with the Securities and Exchange Commission (the 'SEC'), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
